{
  "report_rows": [
    {
      "kpi": "Q2 2026 Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$6.38 vs. cons $6.19",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Total Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$41.0B vs. cons $40.6B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Insurance Segment Benefit Ratio (MLR)",
      "prediction": "BEAT",
      "answer": "pred ~90.9% vs. cons/guided ~91.2%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$9.35-9.50 (raised from 'at least $9.00') vs. cons $9.26 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Total Revenue guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$161-162B (reaffirmed 'at least $160B') vs. cons $162.6B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Insurance segment benefit ratio guidance",
      "prediction": "BETTER",
      "answer": "guide ~92.5% (tightened from 92.75%\u00b125bps) vs. cons 92.75% (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Bonus Year 2028 Star Ratings recovery commentary (qualitative, hybrid/secret-shopper results)",
      "prediction": "BETTER",
      "answer": "guide ~directionally encouraging update implying ~70-80% of MA members trending toward 4-star+ by BY2028 vs. cons/prior uncertainty (~50% probability of full recovery priced by market) (BY2028)",
      "confidence": "LOW"
    },
    {
      "kpi": "Individual MA membership growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~25% vs. cons ~25% (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.7,
  "day5_path": "FADE",
  "day5_rationale": "Q2 beat and a modestly better-than-guided benefit ratio plus an encouraging (if not conclusive) BY2028 Star Ratings update likely drive an initial pop, but with the stock already up >120% from its Feb low and near all-time highs, most of the good news (favorable CMS 2027 rate notice, easing sector cost trends, UNH's clean beat-and-raise) is already priced in. As sell-side digests the print over the following days, focus shifts to the out-period math: 2027 still requires further benefit cuts per management's own commentary on a wider funding-vs.-trend gap, FY2027 consensus EPS still implies a ~46% y/y decline off this year's elevated base, and full BY2028 Star clarity remains pending the Fifth Circuit ruling and CMS's final Star Ratings release in October. That combination of near-term beat but unresolved multi-year Stars/bid uncertainty typically produces partial fade/give-back of the day-1 pop as analysts raise FY26 numbers only modestly while keeping FY27 estimates more cautious.",
  "day5_confidence": "LOW"
}